Prognostic value of N-terminal pro-brain natriuretic peptide in elderly people with acute myocardial infarction: Prospective observational study

BMJ (Online)

Volumn 338, Issue 7704, 2009, Pages 1195-

  Lorgis, L ^a   Zeller, M ^b   Dentan, G ^c   Sicard, P ^b   Buffet, P ^a   L'Huillier, I ^a   Beer, J C ^a   Vincent Martin, M ^d   Makki, H ^d   Gambert, P ^a   Cottin, Y ^a  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c Clinique de Fontaine   (France)

^d Regional Hospital   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ACUTE HEART INFARCTION; ADULT; AGED; AGING; ARTICLE; CAUSE OF DEATH; CORRELATION ANALYSIS; CREATININE CLEARANCE; DIABETES MELLITUS; FEMALE; FOLLOW UP; FRANCE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE WALL; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE LINEAR REGRESSION ANALYSIS; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; PATIENT IDENTIFICATION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK FACTOR; SCORING SYSTEM; SEX DIFFERENCE;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; FRANCE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 67650095559     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.b1605     Document Type: Article

References (36)

1. Masoudi FA, Foody JM, Havranek EP, Wang Y, Radford MJ, Allman RM, et al. Trends in acute myocardial infarction in 4 US states between 1992 and 2001: clinical characteristics, quality of care, and outcomes. Circulation 2006;114:2806-14.
2. Tahir SM, Price LL, Shah PB, Welt FG. Eighteen year (1985-2002) analysis of incidence, mortality, and cardiac procedure outcomes of acute myocardial infarction in patients > or = years of age. Am J Cardiol 2008;101:930-6.
3. Batchelor WB, Anstrom KJ, Muhlbaier LH, Groswald R, Weintraub WS, O'Neill WW, et al. Contemporary outcome trends in the elderly undergoing percutaneous coronary interventions: results in 7,472 octogenarians. J Am Coll Cardiol 2000;36:723-30.
4. Barakat K, Wilkinson P, Deaner A, Fluck D, RanJadayalan K, Timmis A. How should age affect management of acute myocardial infarction? A prospective cohort study. Lancet 1999;353:955-9.
5. Pearte CA, Furberg CD, O'Meara ES, Psaty BM, Kuller L, Powe NR, et al. Characteristics and baseline clinical predictors of future fatal versus nonfatal coronary heart disease events in older adults: the cardiovascular health study. Circulation 2006;113:2177-85.
6. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-28.
7. Martinez-Rumayor A, Richards AM, Burnett JC, Januzzi JL Jr. Biology of the natriuretic peptides. Am J Cardiol 2008;101:3-8.
8. De Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:1014-21.
9. Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Herlitz J, et al. N-terminal pro B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002;106:2913-8.
10. Davis KM, Fish LC, Minaker KL, Elahi D. Atrial natriuretic peptide levels in the elderly: differentiating normal aging changes from disease. J Gerontol A Biol Sci Med 1996;51:M95-101.
11. Luchner A, Burnett JC Jr, JougasakiM, Hense HW, Heid IM, Muders F, et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens 2000;18:1121-8.
12. Sayama H, Nakamura Y, Saito N, Kinoshita M. Why is the concentration of plasma brain natriuretic peptide in elderly patients greater than normal? Coron Artery Dis 1999;10:537-40.
13. Richards AM, Nicholls MG, Espiner E, Lainchbury JG, Troughton RW, Elliott J, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003;107:2786-92.
14. Drewniak W, Snopek G, Zarukiewicz M, Borys M, Da̧browski M. Prognostic value of the N-terminal pro-B-type natriuretic peptide in the elderly with acute myocardial infarction. Kardiol Pol 2008;66:750-5.
15. Vergès B, Zeller M, Beer JC, Cottin Y, RICO Survey Working Group. Plasma N-terminal pro-brain natriuretic peptide (Nt-proBNP) level and prognosis after myocardial infarction in diabetes. Diabetes Metab 2008;34(suppl 1):S10-5.
16. Alpert JS, Thygesen K, Antman E, Bassand JP.Myocardial infarction redefined - a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J AmColl Cardiol 2000;36:959-69.
17. Fox KA, DabbousOH, Goldberg RJ, Pieper KS, Eagle KA, Van deWerf F, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ 2006;333:1091.
18. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
19. Omland T, de Lemos JA, Morrow DA, Antman EM, Cannon CP, Hall C, et al. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol 2002;15;463-5.
20. James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction ofmortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 2003;108:275-81.
21. Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 2002;40:437-45.
22. Jernberg T, Lindahl B, Siegbahn A, Andren B, Frostfeldt G, Lagerqvist B, et al. N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. J AmColl Cardiol 2003;42:1909-16.
23. Galvani M, Ferrini D, Ottani F. Natriuretic peptides for risk stratification of patients with acute coronary syndromes. Eur J Heart Fail 2004;15;6:327-33.
24. Wang TJ, Larson MG, Levy D, Leip EP, Benjamin EJ, Wilson PW, et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 2002;90:254-58.
25. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005;13:1609-16.
26. Raizada V, Thakore K, Luo W, McGuire PG. Cardiac chamber-specific alterations of ANP and BNP expression with advancing age and with systemic hypertension. Mol Cell Biochem 2001;16:137-40.
27. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90:195-203.
28. Omland T, Aakvaag A, Bonarjee VV, Caidahl K, Lie RT, Nilsen DW, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction: comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996;93:1963-9.
29. Clarck BA, Elahi D, Shannon RP, Wei JY, Epstein FH. Influence of age and dose on the end-organ response to atrial natriuretic peptide in humans. Am J Hypertension 1991;4:500-7.
30. Giannessi D, AndreassiMG, Del Ry S, Clerico A, Colombo MG, Dini N. Possibility of age regulation of the natriuretic peptide C-receptor in human platelets. J Endocrinol Invest 2001;24:8-16.
31. Hong M, Yan Q, Tao B, Boersma A, Han KK, Vantyghem MC, et al. Estradiol, progesterone and testosterone exposures affect the atrial natriuretic peptide gene expression in vivo in rats. Biol Chem Hoppe Seyler 1992;373:213-8.
32. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002;40:976-82.
33. Sinclair H, Paterson M, Walker S, Beckett G, Fox KA. Predicting outcome in patients with acute coronary syndrome: evaluation of B-type natriuretic peptide and the Global Registry of Acute Coronary Events (GRACE) risk score. Scott Med J 2007;52:8-13.
34. Jourdain P, Jondeau G, Funck F, Gueffet P, LeHelloco A, Donal E, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP multicenter study. J Am Coll Cardiol 2007;49:1733-9.
35. Mueller C. The use of B-type natriuretic peptides in coronary artery disease: utile or futile? J Am Coll Cardiol 2007;50:215-6.
36. White HD, Chew DP. Acute myocardial infarction. Lancet 2008;372:570-84.